Results 81 to 90 of about 180,299 (231)
BMC Research Notes, 2018 Objective Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis.
Md Golam Hasnain +7 more
doaj +1 more source
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
Parasites & Vectors, 2017 BackgroundMiltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL.
Saumya S. Srivastava +5 more
semanticscholar +1 more source
Neuroimmune Pain and Its Manipulation by Pathogens
Evolutionary Applications, Volume 18, Issue 4, April 2025.ABSTRACT Recent studies highlight extensive crosstalk that exists between sensory neurons responsible for pain and the immune system. Cutaneous pain neurons detect harmful microbes, recruit immune cells, and produce anticipatory immunity in nearby tissues. These complementary systems generally protect hosts from infections.
Kevin W. Lozo +2 more
wiley +1 more source
Visceral Leishmaniasis Treatment, Italy [PDF]
Emerging Infectious Diseases, 2003 First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%.
Luigi Gradoni +2 more
openaire +3 more sources
Chemotherapeutics of visceral leishmaniasis: present and future developments
Parasitology, 2017 SUMMARY Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination.
S. Sundar, Anup Singh
semanticscholar +1 more source
The FEBS Journal, Volume 292, Issue 8, Page 1868-1883, April 2025.Traditionally, adipocytes have been viewed as energy storage units, which upregulate inflammatory factors in response to obesity. However, emerging evidence demonstrates that adipocytes are highly responsive to systemic infection, and upregulate cytokines and antimicrobial compounds in response.
Matthew C. Sinton, Shingo Kajimura
wiley +1 more source
Challenges in Modeling Complexity of Neglected Tropical Diseases: Assessment of Visceral Leishmaniasis Dynamics in Resource Limited Settings [PDF]
arXiv, 2016 Neglected tropical diseases (NTD), particularly vector-borne diseases (VBD), account for a large proportion of the global disease burden, and their control faces several challenges including diminishing human and financial resources for those distressed from such diseases.
arxiv
HIV-associated visceral leishmaniasis [PDF]
Clinical Microbiology and Infection, 2001 Visceral leishmaniasis (VL) is a severe disease caused by protozoa of the genus Leishmania that usually affects immunocompetent hosts in endemic areas [1,2]. Since the mid-1980s, VL has been recognized as an opportunistic infection associated with some immunodeficiency states, such as neoplasms, organ transplantation, or treatment with ...
Vicente Pintado, R. López-Vélez
openaire +3 more sources
Leishmaniasis–HIV coinfection: current challenges
HIV/AIDS: Research and Palliative Care, 2016 José Angelo Lauletta Lindoso,1,2 Mirella Alves Cunha,3 Igor Thiago Queiroz,4 Carlos Henrique Valente Moreira2 1Laboratory of Soroepidemiology (LIM HC-FMUSP), São Paulo University, São Paulo, 2Instituto de Infectologia Emilio ...
Lindoso JAL +3 more
doaj
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent
eLife, 2016 Leishmania donovani causes visceral leishmaniasis (VL), the second most deadly vector-borne parasitic disease. A recent epidemic in the Indian subcontinent (ISC) caused up to 80% of global VL and over 30,000 deaths per year. Resistance against antimonial
H. Imamura +32 more
semanticscholar +1 more source